Introduction

Multiple myeloma is a type of cancer that affects plasma cells, which are crucial components of your immune system. While significant progress has been made in understanding and treating this disease, ongoing research continues to explore new and innovative therapies.

Clinical trials play a vital role in this advancement, offering patients access to cutting-edge treatments and contributing to the development of improved care for future generations. 

This report aims to provide you, as a patient, with a comprehensive understanding of clinical trials in multiple myeloma, the current treatment landscape, and what the future holds.

Overview of multiple myeloma

Multiple myeloma is a cancer that begins in the bone marrow, the spongy tissue inside some of your bones where blood cells are made. [1] Healthy plasma cells produce antibodies that help fight infections. 

In multiple myeloma, these plasma cells become abnormal, multiply uncontrollably, and produce an ineffective protein called monoclonal protein or M-protein. [1] This buildup of abnormal plasma cells can crowd out healthy blood cells, leading to problems such as anemia (low red blood cell count), increased risk of infections (low white blood cell count), and bleeding or bruising easily (low platelet count). [1]

The M-protein can also build up in the blood and urine, potentially damaging organs like the kidneys. [1] Additionally, myeloma can weaken bones, causing pain, fractures, and other bone-related issues. [1].

Common symptoms of multiple myeloma may include bone pain, often in the back or ribs, fractures, weakness or fatigue, weight loss, frequent infections, excessive thirst, and frequent urination. [2].

It's important to remember that multiple myeloma is a complex disease with varying stages and treatment approaches tailored to each individual. [3]

Understanding clinical trials and their importance

Clinical trials are research studies that involve people who volunteer to test new medical treatments, procedures, or devices to see how well they work and if they are safe. [4]

These studies are essential for improving patient care because they help determine if new drugs or treatments are more effective than existing ones, have fewer or less harmful side effects, or both. [5] 

In the field of multiple myeloma, clinical research is particularly robust, with many ongoing trials exploring innovative therapies. [5]

Participating in a clinical trial can offer you access to treatments that are not yet widely available, potentially providing benefits that go beyond the current standard of care. [6]

By volunteering, you also contribute to the advancement of medical knowledge, helping doctors and researchers learn more about multiple myeloma and develop better treatments for future patients. [7]

It is important to understand that participation in a clinical trial is entirely voluntary, and you have the right to leave the trial at any time. [5]

Clinical trials landscape

The landscape of clinical trials for multiple myeloma is dynamic and constantly evolving, reflecting the ongoing efforts to improve treatment outcomes. [8]

• Numerous clinical trials are currently underway, exploring various new therapies and treatment combinations. [5]

• These trials are conducted globally at major medical centers, universities, and community hospitals, notably in the United States, China, Germany, France, Spain, and Australia. [9]

• The National Cancer Institute (NCI) website lists over 200 active treatment trials specifically for multiple myeloma. [10]

• This extensive research underscores the medical community’s commitment to improving management and treatment strategies for multiple myeloma.[5]

• Key research areas include: Testing new drugs, combining existing drugs in novel ways, exploring different treatment sequences and investigating innovative approaches like immunotherapy and cell-based therapies. [6] 

• The ultimate goal is to develop more precise, effective treatments tailored to individual patient needs, resulting in longer remissions and enhanced quality of life. [11]

Types of trials (phase I-IV)

Clinical trials are conducted in phases, each designed to answer specific questions about a new treatment. [15]. Understanding these phases can help you better navigate the clinical trial process.

Phase I trials:

• Typically the first studies to test new treatments in humans. [12]
  
  
  

• Main objectives: Determine treatment safety, Identify the highest safe dose without severe side effects and understand how the treatment affects the body. [12]
  
  
  

• Usually involve a small number of participants, often those with advanced myeloma resistant to standard treatments. [12]
  
  
  

• While some patients may benefit, primary focus remains on safety and dosage determination for further trials. [13]
  
  
  

Phase II trials:

• Conducted if Phase I trials show the treatment is safe. [13]
  
  
  

• Purpose is to evaluate the effectiveness of the treatment for specific cancers like multiple myeloma. [13]
  
  
  

• Typically involve a larger group (25 to 100 patients) with the same type of cancer, treated with the safest and most effective dose identified in Phase I. [13]
  
  
  

• Researchers monitor if the treatment shrinks the cancer, slows growth, or offers other benefits, while continuing to assess side effects. [13]
  
  
  

Phase III trials:

• Involve large patient populations, often hundreds to thousands, comparing new treatment safety and effectiveness against current standard treatments. [13]
  
  
  

• Participants are usually randomly assigned to receive either the new or standard treatment. [13]
  
  
  

• Trials often occur at multiple locations nationally or internationally. [13]
  
  
  

• If a treatment demonstrates superior or comparable efficacy with fewer side effects compared to standard therapy, it may be considered for approval by regulatory authorities (e.g., FDA). [14]
  
  
  

Phase IV trials:

• Conducted after treatment has received FDA approval and is publicly available. [15]
  
  
  

• Aim to continue evaluating long-term safety and effectiveness in larger, more diverse patient populations over extended periods.[16]
  
  
  

• Researchers may study treatment effectiveness in specific patient groups or compare it with existing treatments on the market. [16]

Common endpoints measured

In multiple myeloma clinical trials, researchers look at specific outcomes, known as endpoints, to determine if a treatment is working. [17]

These endpoints are carefully chosen to measure the impact of the treatment on the disease and your health. Some common endpoints in myeloma trials include:

• Overall survival (OS): This measures how long patients live after starting treatment, regardless of the cause of death [18]. While OS is a critical endpoint, it can take a long time to observe in myeloma trials because newer treatments are helping patients live longer. [18]

• Progression-free survival (PFS): This measures the length of time during and after treatment that a patient lives with the disease without it getting worse. [19] PFS is often used to evaluate how well a treatment can delay disease progression. [20]

• Overall response rate (ORR): This is the percentage of patients who have a noticeable reduction in their cancer after treatment within a specific timeframe.Responses can range from a partial response (PR), where the cancer has decreased significantly, to a complete response (CR), where standard tests show no signs of myeloma cells. [21]

• Minimal residual disease (MRD): This is a highly sensitive measure that checks for any remaining myeloma cells after treatment, even when traditional tests show remission.[22] Achieving MRD negativity, meaning no detectable myeloma cells remain, indicates a deeper response to treatment and is increasingly being used as an endpoint in myeloma trials. [22]

Researchers may also look at other endpoints such as time to progression (TTP), duration of response (DoR), clinical benefit rate (CBR), safety and tolerability, and quality of life (QoL). [23]

Understanding these endpoints can help you and your healthcare team assess the potential benefits of participating in a clinical trial.

Regulatory and ethical considerations

• Clinical trials in multiple myeloma, like all medical research involving human participants, follow strict regulatory and ethical guidelines. [24]
  
  
  

• These guidelines protect your safety, rights, and well-being throughout the research process. [5]
  
  
  

• In the United States, the Food and Drug Administration (FDA) oversees clinical trials to ensure ethical and scientific conduct. [5]
  
  
  

• Clinical trials must be reviewed and approved by an Institutional Review Board (IRB) before they can begin. [24]
  
  
  

• An IRB is an independent committee of doctors, researchers, and community members ensuring studies are ethical and that participant risks are minimized and reasonable compared to potential benefits. [24]
  
  
  

• Informed consent is a crucial ethical consideration. It involves your healthcare team providing detailed information about: Purpose of the trial, procedures involved, potential risks and benefits, alternative treatments
  and your right to withdraw at any time. [5]
  
  
  

• You will have the opportunity to ask questions and discuss the trial with your family and healthcare team before making a participation decision. [7]
  
  
  

• If you decide to participate, you'll sign an informed consent form indicating you understand and agree to take part. [7]
  
  
  

• Throughout the trial, your privacy and the confidentiality of your medical information are strictly protected. [7]

Current standard of care

The standard of care for multiple myeloma has significantly advanced in recent years, leading to improved outcomes for many patients [8]. The initial treatment approach for newly diagnosed multiple myeloma depends on factors such as whether you are eligible for a stem cell transplant. [25]

For transplant-eligible patients:

• A typical approach starts with induction therapy, usually a combination of three or four drugs to reduce myeloma cells. [25]
  
  
  

• Common drug combinations include: Immunomodulatory drugs (e.g., lenalidomide, pomalidomide), proteasome inhibitors (e.g., bortezomib, carfilzomib, ixazomib) and steroids (e.g., dexamethasone) [25]
  
  
  

• Sometimes, a monoclonal antibody (e.g., daratumumab, isatuximab) is added. [26]
  
  
  

• After induction therapy, stem cells are collected, and patients receive high-dose chemotherapy followed by autologous stem cell transplant (ASCT), infusing their own stem cells back into their body. [25]
  
  
  

• Post-transplant maintenance therapy, often with lenalidomide, is used to help prevent relapse.[25]
  
  
  

For transplant-ineligible patients:

• Initial treatment also involves combination drug therapy, similar to the drugs used in transplant-eligible patients. [25]
  
  
  

• Treatment may continue until disease progression. [27]
  
  
  

• Recently approved treatments include quadruplet drug combinations as initial therapy for these patients. [28]
  
  
  

When multiple myeloma relapses or becomes refractory:

• Treatment options include: repeating previously effective therapies, trying different drug combinations used during initial treatment and using newer therapies such as monoclonal antibodies, bispecific antibodies, and CAR T-cell therapy [25]
  
  
  

• Choice of therapy at relapse depends on factors like: Previous therapies received, speed of myeloma return, overall patient health and genetic abnormalities in myeloma cells [29]

Approved therapies

Over the years, numerous therapies have been approved by the FDA for the treatment of multiple myeloma, reflecting the significant progress in this field [30]. These include:

• Proteasome iInhibitors: Bortezomib (Velcade), Carfilzomib (Kyprolis), Ixazomib (Ninlaro). [42]

• Immunomodulatory drugs (IMiDs): Thalidomide (Thalomid), Lenalidomide (Revlimid), Pomalidomide (Pomalyst). [42]

• Monoclonal antibodies: Daratumumab (Darzalex), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro), Elotuzumab (Empliciti), Isatuximab-irfc (Sarclisa). [42]

• Bispecific antibodies: Teclistamab-cqyv (Tecvayli), Talquetamab-tgvs (Talvey), Elranatamab-bcmm (Elrexfio). [42]

• Cell and gene therapies (CAR T-cell therapy): Idecabtagene vicleucel (Abecma), Ciltacabtagene autoleucel (Carvykti). [42]

• Alkylating qgents: Melphalan (Alkeran, Evomela), Cyclophosphamide (Cytoxan), Bendamustine (Treanda or Bendeka). [42]

• Corticosteroids: Dexamethasone, Prednisone. [42]

• Other therapies: Selinexor (Xpovio), Belantamab mafodotin-blmf (Blenrep - currently withdrawn in the US but may be available in clinical trials or for patients continuing treatment). [42]

This list is not exhaustive, and new therapies are continually being developed and approved. Your healthcare team will determine the most appropriate treatment plan based on your individual circumstances.

Scope of improvement

• Despite significant advancements in treating multiple myeloma, several unmet medical needs remain. [31]
  
  
  

• Multiple myeloma remains largely incurable, with most patients eventually relapsing.
  
  
  

• Development of therapies providing long-term remissions or a cure is a critical unmet need. [32]
  
  
  

• Treatment of relapsed and refractory multiple myeloma, particularly for patients resistant to multiple therapy lines, is challenging. [31]
  
  
  

• Newer therapies like CAR T-cell therapy and bispecific antibodies show promise, but further improvements are needed to achieve durable responses. [31]
  
  
  

• Certain patient subgroups, including those with high-risk cytogenetic features, extramedullary disease (myeloma cells growing outside the bone marrow), or kidney failure, often experience poorer outcomes. [31]
  
  
  

• Developing therapies specifically targeting high-risk features is essential.
  
  
  

• Managing side effects and toxicities associated with current treatments remains challenging, impacting patients' quality of life. [26]
  
  
  

• There is a need for effective and better-tolerated therapies, especially for older and frailer patients with additional health conditions. [28]
  
  
  

• Disparities in access to care and clinical trials exist, especially among racial and ethnic minority groups, highlighting the need for more inclusive research and treatment strategies. [33]
  
  
  

Addressing these unmet needs through ongoing research and clinical trials is crucial for improving outcomes for individuals affected by multiple myeloma.

Emerging therapies

The field of multiple myeloma research is rapidly evolving, with several promising new therapies emerging that aim to address the unmet medical needs. [34]

These emerging therapies include novel drug therapies, cell and gene therapies, immunotherapy, and targeted therapies.

Novel drug therapies :

• Researchers are continuously exploring new drugs with different mechanisms of action to overcome resistance and improve outcomes in multiple myeloma. [35]
  
  
  

• Some novel drug therapies under investigation include:
  
  
  

  • Next-generation proteasome inhibitors and IMiDs: newer versions of existing drug classes that may offer improved efficacy and tolerability. [36]
    
    
    

  • Selinexor: works by blocking a protein called XPO1, which can help stop the growth of myeloma cells. [30]
    
    
    

  • Melflufen: a peptide-drug conjugate that delivers an alkylating agent directly to myeloma cells. [31]
    
    
    

  • Iberdomide and Mezigdomide: next-generation cereblon E3 ligase modulators (CELMoDs) that have shown promising activity in relapsed/refractory myeloma. [28]
    
    
    

  • Vactosertib: being investigated in steroid-free myeloma regimens.
    
    
    

• Clinical trials are underway to evaluate the safety and effectiveness of these novel agents, both as single therapies and in combination with existing treatments. [35]
  
  
  

Cell and gene therapies :

• Cell and gene therapies, particularly CAR T-cell therapy, have shown remarkable success in treating relapsed/refractory multiple myeloma. [37]
  
  
  

• CAR T-cell therapy involves taking your own T cells (a type of immune cell), modifying them in the lab to recognize and attack myeloma cells, and then infusing them back into your body. [38]
  
  
  

• Several CAR T-cell therapies targeting BCMA (B-cell maturation antigen) on myeloma cells have been approved, and research is ongoing to improve their effectiveness and safety. [30]
  
  
  

• Advancements in this area include new delivery methods, human-based CAR T-cell products, targeting new antigens, and the development of off-the-shelf (allogeneic) CAR T-cell therapies. [37]
  
  
  

Immunotherapy and targeted therapies :

• Immunotherapy harnesses the power of your immune system to fight cancer. [38]
  
  
  

• Monoclonal antibodies, such as daratumumab and isatuximab, target specific proteins on myeloma cells, leading to their destruction. [39]
  
  
  

• Bispecific antibodies are another form of immunotherapy that have two arms: one arm binds to a myeloma cell, and the other arm binds to a T cell, bringing them together to kill the myeloma cell. [30]
  
  
  

• Several bispecific antibodies have been approved for relapsed/refractory myeloma, and many more are in development. [37]
  
  
  

• Targeted therapies aim to attack specific vulnerabilities within cancer cells. [38]
  
  
  

• While many existing myeloma drugs have targeted effects, research continues to identify new targets and develop more specific therapies. [36]

Future perspectives

The future of clinical trials in multiple myeloma holds great promise for further advancements in treatment and care.

Enhancing collaboration

• Enhancing collaboration among researchers, clinicians, industry partners, patient advocacy groups, and regulatory agencies is crucial for accelerating progress in myeloma research. [40]
  
  
  

• Collaborative efforts can help streamline clinical trial processes, improve trial design, increase patient enrollment, and ensure research addresses the most pressing needs of the myeloma community. [41]
  
  
  

• Patient advocacy groups play a vital role in shaping research priorities, providing the patient perspective, and advocating for policies supporting myeloma research and access to care. [40]
  
  
  

• International collaborations are essential for conducting large-scale clinical trials and sharing knowledge globally. [28]
  
  
  

Improving patient education

• Improving patient education about multiple myeloma and clinical trials is essential for empowering patients to make informed decisions about their care. [5]
  
  
  

• Providing clear, accessible, and comprehensive information about the disease, treatment options, clinical trial processes, and potential benefits and risks of participation can help reduce anxiety and increase patient engagement in research. [7]
  
  
  

• Utilizing online platforms, support groups, and educational materials developed in collaboration with patient advocacy organizations can enhance patient understanding and facilitate shared decision-making with healthcare providers. [5]

Conclusion

Navigating clinical trials in multiple myeloma can seem complex, but understanding the process, the importance of research, and your rights as a patient is empowering. 

The current landscape of myeloma treatment is rapidly evolving, with numerous ongoing clinical trials exploring innovative therapies. By understanding the different phases of clinical trials, common endpoints, and the regulatory and ethical considerations, you can have informed discussions with your healthcare team about whether participating in a clinical trial is the right choice for you. 

While unmet medical needs remain, the future holds great promise with emerging therapies and advancements in clinical trial methodologies. 

Enhancing collaboration and improving patient education will be key to accelerating progress and improving the lives of individuals living with multiple myeloma. 

Remember that you are not alone in this journey, and numerous resources and support systems are available to help you navigate the complexities of multiple myeloma care and research.

References

1. What is Multiple Myeloma? Symptoms, Causes, & Prognosis
   https://themmrf.org/multiple-myeloma/ 

2. Multiple myeloma - Symptoms and causes - Mayo Clinic
   https://www.mayoclinic.org/diseases-conditions/multiple-myeloma/symptoms-causes/syc-20353378

3. Multiple Myeloma: Symptoms, What It Is, Prognosis & Treatment - Cleveland Clinic
   https://my.clevelandclinic.org/health/diseases/6178-multiple-myeloma

4. Understanding Clinical Trials| Intrnt'l Myeloma Foundation
   https://www.myeloma.org/resource-library/understanding-clinical-trials-myeloma

5. What Is a Clinical Trial | International Myeloma Foundation
   https://www.myeloma.org/clinical-trial-search 

6. Multiple Myeloma Clinical Trials & Research - Memorial Sloan Kettering Cancer Center
   https://www.mskcc.org/cancer-care/types/multiple-myeloma/clinical-trials

7. Clinical trials in multiple myeloma: What is there to know? | This Is Living With Cancer
   https://www.thisislivingwithcancer.com/content/Clinical_trials_in_multiple_myeloma_What_is_there_to_know

8. The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies - MDPI
   https://www.mdpi.com/2072-6694/17/3/525

9. Clinical Trial Trends: Multiple Myeloma - Precision For Medicine
   https://www.precisionformedicine.com/blog/clinical-trial-trends-multiple-myeloma
   
   

10. Treatment Clinical Trials for Multiple Myeloma/Plasma Cell Myeloma - NCI
    https://www.cancer.gov/research/participate/clinical-trials/disease/multiple-myeloma-plasma-cell-myeloma/treatment

11. Clinical trials for multiple myeloma treatment - MatchTrial
    https://matchtrial.health/en/clinical-trials/multiple-myeloma-treatment-clinical-trials/

12. Definition of phase I clinical trial - NCI Dictionary of Cancer Terms
    https://www.cancer.gov/publications/dictionaries/cancer-terms/def/phase-i-clinical-trial

13. Types and Phases of Clinical Trials | What Are Clinical Trial Phases https://www.cancer.org/cancer/managing-cancer/making-treatment-decisions/clinical-trials/what-you-need-to-know/phases-of-clinical-trials.html

14. Definition of phase 3 clinical trial - NCI Dictionary of Cancer Terms
    https://www.cancer.gov/publications/dictionaries/cancer-terms/def/phase-3-clinical-trial

15. About cancer clinical trials - Mayo Clinic
    https://www.mayoclinic.org/departments-centers/mayo-clinic-cancer-center/cancer-care/about-cancer-clinical-trials

16. What is a Phase 4 Clinical Trial? And Why is it Important? - Roche
    https://www.roche.com/stories/phase-4-clinical-trials 

17. Oncology (Medical) - Clinical trials - Mayo Clinic
    https://www.mayoclinic.org/departments-centers/oncology/sections/clinical-trials/rsc-20198231?page=17&citems=10%2C10.html

18. Overall Survival (OS) - HealthTree for Multiple Myeloma
    https://healthtree.org/myeloma/guides/clinical-trial-endpoints-guide/myeloma-clinical-trials

19. Clinical Trial Glossary | International Myeloma Foundation
    https://www.myeloma.org/clinical-trial-glossary

    
    

20. Progression-Free Survival - HealthTree for Multiple Myeloma
    https://healthtree.org/myeloma/guides/clinical-trial-endpoints-guide/progression-free-survival

    
    

21. Overall Response Rate (ORR) - HealthTree for Multiple Myeloma
    https://healthtree.org/myeloma/guides/clinical-trial-endpoints-guide/overall-response-rates

    
    

22. Minimal Residual Disease - HealthTree for Multiple Myeloma
    https://healthtree.org/myeloma/guides/clinical-trial-endpoints-guide/minimal-residual-disease

    
    

23. What are Common Endpoints in Myeloma Clinical Trials? 
    https://healthtree.org/myeloma/guides/clinical-trial-endpoints-guide/common-endpoints-myeloma-trials

    
    

24. Ethical Considerations for Oncology Clinical Trials | Biodexa
    https://biodexapharma.com/patient-resource/ethical-considerations-for-oncology-clinical-trials/

    
    

25. Multiple Myeloma Treatments | Drugs & Treatment by Stage 
    https://themmrf.org/diagnosis-and-treatment/treatment-options/

    
    

26. Newly Diagnosed Multiple Myeloma - The ASCO Post
    https://ascopost.com/issues/march-10-2024/newly-diagnosed-multiple-myeloma/

    
    

27. Short overview on the current standard of treatment
    https://pmc.ncbi.nlm.nih.gov/articles/PMC5862912/ 

    
    

28. Progress in the Field of Myeloma
    https://www.myeloma.org/blog/progress-field-myeloma-past-present-future

    
    

29. Multiple Myeloma | Relapsed and Refractory Myeloma | LLS
    https://www.lls.org/myeloma/treatment/refractory-and-relapsed

    
    

30. FDA Approved Multiple Myeloma Drugs
    https://www.myeloma.org/multiple-myeloma-drugs

    
    

31. Unmet Needs in Multiple Myeloma and Potential Solutions
    https://ashpublications.org/blood/article/144/Supplement%201/6907/527598/Unmet-Needs-in-Multiple-Myeloma-and-Potential

    
    

32. Addressing Unmet Needs in Multiple Myeloma Research
    https://www.sanofi.com/en/magazine/

    
    

33. Unmet Needs in Multiple Myeloma
    https://www.mmcalltoaction.com/unmet-needs/

    
    

34. Emerging therapies for relapsed/refractory multiple myeloma
    https://pmc.ncbi.nlm.nih.gov/articles/PMC8299593/

    
    

35. Novel Drug Combination in Multiple Myeloma - The ASCO Post
    https://ascopost.com/news/march-2024/novel-drug-combination-in-multiple-myeloma/

    
    

36. Novel agents in multiple myeloma - PMC
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6589825/

    
    

37. IMS 2024: New Myeloma Immunotherapy Strategies
    https://healthtree.org/myeloma/community/articles/ims-2024

    
    

38. Multiple myeloma - Diagnosis and treatment - Mayo Clinic
    https://www.mayoclinic.org/diseases-conditions/multiple-myeloma/diagnosis-treatment/drc-20353383

    
    

39. FDA Approvals Expand Initial Treatment Options
    https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-daratumumab-isatuximab-newly-diagnosed-myeloma

    
    

40. Including the patient voice
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6978854/

    
    

41. Multiple Myeloma Research Foundation's Horizon Clinical Trial
    https://www.appliedclinicaltrialsonline.com/view/multiple-myeloma-research-foundation-horizon-clinical-trial

    
    

42. US Food and Drug Administration
    https://www.fda.gov/